The idea behind mRNA medicine is older than most of the people reading about it. Researchers first got mRNA into cells to make a protein in 1978; the first successful animal experiments came in 1990; the first approved drug arrived in 2020. So what is mrna technology, if the concept is more than forty years old? It is a set of engineering solutions to a delivery problem — how to get fragile instructions into the right cells without the body destroying them first.
The Short Answer
Messenger RNA is the intermediate between DNA and protein: a temporary working copy of a gene. mRNA technology uses synthetic versions of that molecule. Deliver a strand into a cell and the cell’s own ribosomes read it and build whatever protein it encodes. The cell does the manufacturing; the drug is just the instruction.
Why Naked mRNA Does Not Work
Three problems defeated researchers for decades. RNA is chemically fragile — enzymes called RNases are everywhere, including on your skin, and they shred it. RNA is large and negatively charged, so it cannot cross the cell membrane on its own. And the immune system treats stray RNA as a sign of viral infection, which is usually exactly what it is.
Early experiments caused inflammation severe enough to stop programmes entirely. Getting past that took two separate breakthroughs.
Breakthrough One: The Lipid Nanoparticle
The solution was to wrap the mRNA in a bubble of fat. Lipid nanoparticles are roughly 100 nanometres across and built from four components: an ionisable lipid that binds the RNA and releases it inside the cell, a phospholipid for structure, cholesterol for stability, and a PEG-lipid that stops the particle being cleared too quickly.
The ionisable lipid is the clever part. It is positively charged at low pH, which lets it grab the negatively charged RNA during manufacture, and neutral at blood pH, which reduces toxicity. Inside the cell’s acidic endosome it picks up charge again, disrupts the endosome membrane, and releases its cargo.
Breakthrough Two: The Pseudouridine Fix
In 2005 Katalin Kariko and Drew Weissman at the University of Pennsylvania published a paper explaining why injected mRNA caused inflammation. The immune system’s Toll-like receptors recognise uridine, one of RNA’s four letters, in certain contexts. Replace uridine with a slightly modified version called pseudouridine and the inflammatory response largely disappears.
The work was largely ignored for years — Kariko’s funding was cut and she was moved between labs — before becoming the foundation of the whole field. Kariko and Weissman received the 2023 Nobel Prize in Physiology or Medicine.
What Has Actually Been Approved
| Application | Status | Notes |
|---|---|---|
| COVID-19 vaccines | Approved and widely used since 2020 | The first mRNA products to reach large-scale use |
| RSV vaccine | Approved 2023-2024 | First mRNA vaccine for a non-COVID target in general use |
| Personalised cancer vaccines | In clinical trials | Built from a patient’s own tumour mutations; phase 3 trials underway |
| Rare metabolic disease, cystic fibrosis | Early-phase trials | Goal is to supply a working protein the patient lacks |
Note the pattern in that table. Everything approved so far either triggers an immune response or is given in small, repeated doses. The harder applications are still in trials, and some will not work out.
The Real Limits
mRNA is transient by design. It gets degraded within hours to days, which makes it good for vaccination, where a brief burst of protein is enough, and difficult for conditions that need a protein replaced continuously.
Getting it to the right tissue is the harder problem. Intramuscular injection mostly affects the injection site and nearby lymph nodes. Reaching the lungs, liver, or bone marrow requires different formulations, and most of that work is unfinished. Repeat dosing is limited too — immune responses against the delivery vehicle can make later doses less effective.
And the storage requirement is real. mRNA needs cold chains; the ultra-cold requirements of the first COVID vaccines were a genuine logistical constraint, particularly outside wealthy countries. None of this means what is mrna technology is overhyped — it means the hard cases take longer than the easy ones, and the easy ones came first.
Keep Exploring
- What is CRISPR? — the other big platform in modern biology
- How does DNA work? — the instructions mRNA is copied from
- Do we only use 10 percent of our brain? — how headlines distort real research
